Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor
نویسندگان
چکیده
منابع مشابه
Lymphocyte‐activation gene‐3, an important immune checkpoint in cancer
Immunotherapy has recently become widely used in lung cancer. Many oncologists are focused on cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed cell death ligand-1 (PD-L1) and programmed cell death-1 (PD-1). Immunotherapy targeting the PD-1/PD-L1 checkpoints has shown promising efficacy in non-small cell lung cancer (NSCLC), but questions remain to be answered. Among them is whether the sim...
متن کاملLag - 3 , a Novel Lymphocyte Activation Gene
A number of cell surface structures are thought to belong to the Ig superfamily (IgSF) t because they contain at least one domain with a characteristic folding pattern, called the Ig fold (reviewed in reference 1) . Several of these molecules have critical functions in immune responses . In addition to ensuring specific antigen recognition (Ig, TCR), they may function as monomorphic ligands cri...
متن کاملLymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia
A novel therapeutic approach in cancer, attempting to stimulate host anti-tumor immunity, involves blocking of immune checkpoints. Lymphocyte activation gene 3 (LAG3) is an immune checkpoint receptor expressed on activated/exhausted T cells. When engaged by the major histocompatibility complex (MHC) class II molecules, LAG3 negatively regulates T-cell function, thereby contributing to tumor esc...
متن کاملCytotoxic T lymphocyte antigen - 4 and immune checkpoint blockade
Introduction The immune system is an important defense against the development and progression of cancer (1). Historically, there has been a waxing and waning enthusiasm for immune therapies to treat cancer due to limited efficacy. Immunotherapies, such as IL-2 and adoptive transfer of autologous tumor-infiltrating lymphocytes, can induce durable tumor responses in a subset of patients, leading...
متن کاملCytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.
The relationship between cancer and the immune system is complex and provides unique therapeutic opportunities. Cytotoxic T lymphocyte antigen-4 (CTLA-4) is a regulatory molecule that suppresses T cell effector function following initial activation by costimulatory signals. Fully human monoclonal antibodies targeting CTLA-4 have been shown to increase T cell function and antitumor responses in ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Seminars in Immunology
سال: 2019
ISSN: 1044-5323
DOI: 10.1016/j.smim.2019.101305